Piper Sandler Downgrades Marker Therapeutics (MRKR) to Neutral
Tweet
Share
E-mailGet Alerts MRKR Hot Sheet
Price: $1.39 +13.93%
Rating Summary:
9 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
9 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Piper Sandler analyst Edward A. Tenthoff downgraded Marker Therapeutics (NASDAQ: MRKR) from Overweight to Neutral with a price target of $2.50 (from $5.00).
For an analyst ratings summary and ratings history on Marker Therapeutics click here. For more ratings news on Marker Therapeutics click here.
Shares of Marker Therapeutics closed at $2.48 yesterday.
You May Also Be Interested In
- H.C. Wainwright Reiterates Buy Rating on Marker Therapeutics (MRKR)
- Cummins (CMI) PT Lowered to $675 at Jefferies
- Flux Power Holdings (FLUX) PT Lowered to $1.60 at Roth/MKM
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
